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Autoimmune progesterone dermatitis 
(APD) is a rare condition, characterised by 
recurrent premenstrual cyclic eruptions.[1] 
It may present with a variety of cutaneous 
and mucosal manifestations but urticaria, 
erythema multiforme, eczematous, and 
vesicular or papulovesicular eruptions are 
the most common. APD is considered to be 
a hypersensitivity reaction to an increased 
level of endogenous progesterone during the 
luteal phase of the menstrual cycle. Exposure 
to exogenous progesterone plays a big role 
in the pathogenesis of APD. APD was first 
reported by Gerber[1] in 1921.[2,3] 
Case report 
A 30-year-old black, uniparous woman with 
no significant past dermatological history and 
no prior exogenous hormone presented at the 
clinic complaining of persistent cyclic skin 
eruptions and urticaria of over 2 months. She 
reported that symptoms started immediately 
before getting her normal menstrual cycle 
after medical abortion. She noted that the 
pruritic skin lesions were exacerbated 4 - 5 
days before the onset of her menses, lasted for 
~5 days, and partially improved within 1 - 2 
days after the end of the menses. There was 
no complete clearance of the lesions between 
menstrual cycles. When she first reported the 
symptoms to her GP, the initial diagnosis was 
allergic contact dermatitis and topical steroids 
were prescribed but only slight improvement 
was shown. 
Clinical examination revealed urticaria, 
pete chiae and palpable pinpoint purpura 
lesions, distributed over the legs, forearms, 
neck and buttocks (Fig. 1, A - D). The pre-
sumptive diagnosis of autoimmune pro ges-
terone dermatitis was made. An intradermal 
skin test using 0.1 cc of progesterone was 
performed. The patient immediately deve-
loped a wheal, confirming the diagnosis 
of APD. She was reluctant to have a skin 
biopsy. No abnormal values were found in 
the routine blood chemistry and hormonal 
examinations. 
A continuous regimen of an oral contra-
ceptive pill with 30 mg ethinyl oestradiol and 
0.15 mg of levonorgestrel was started on the 
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Autoimmune progesterone dermatitis (APD) is a rare autoimmune response to raised endogenous progesterone levels that occur during the 
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Fig. 1. Autoimmune progesterone dermatitis. Pruritic, erythematous, and urticarial papules on (A) left 
forearm; (B) right forearm; (C) left leg; and (D) left side of the neck and face. 
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patient. The skin eruptions have not returned since the initiation of 
this therapy.
The medical report request was sent to her first GP and he 
confirmed that the medical abortion was induced using mifepristone 
600 mg with tabs misoprostol (400 mg start then 200 mg three times a 
day for 4 days). Routine serum β hCG tests, antibiotics and anti-pain 
medications were also prescribed. 
APD manifests via the occurrence of cyclic skin eruptions. Women 
with the disorder commonly present with dermatological lesions in the 
luteal phase of the menstrual cycle.[4,5] Diagnosis of APD is confirmed 
by performing a skin allergen test using progesterone.[5] Due to its rarity, 
APD should be considered a diagnosis of exclusion.[6-9] In this case, we 
believe symptoms occurred as a result of increased hypersensitivity to 
endogenous progesterone, triggered immediately after medical abortion. 
Discussion
Hormones of the anterior pituitary gland are relatively inactive prior 
to puberty. They are usually released 2 - 3 years prior to puberty 
after the initial release of gonadotropin-releasing hormone (GnRH) 
by the hypothalamus.[10] It is still uncertain what triggers this sudden 
increase in GnRH a few years after puberty. GnRH is released in 
a rhythmic, pulsatile manner resulting in the pulsatile release of 
luteinising hormone (LH) and follicle-stimulating hormone (FSH) by 
the anterior pituitary gland.[10-12] The primary function of FSH is to 
stimulate the granulosa cells of the ovary to synthesise oestrogen.[12] For 
transformation of the oestrogen-secreting stromal cells of the ovary to 
progestogen-secreting cells, LH is needed. Apart from the stimulation 
of progesterone production, LH is essential for final oocyte maturation 
and the trigger of ovulation.[10] 
Progesterone is secreted by the ovary mainly from the corpus 
luteum during the second half of the menstrual cycle.[11] Secretion 
actually begins just before ovulation from the follicle that is 
destined to release an ovum. Progesterone, like all other steroid 
hormones, is synthesised from pregnenolone, which in turn is 
derived from cholesterol. It occurs in the ovary, testes, adrenal cortex 
and placenta. [10,11] The stimulatory effect of LH on progesterone 
synthesis and secretion by the corpus luteum is mediated by a 
membrane-bound receptor linked to a G-protein-coupled signal 
transduction pathway that increases the synthesis of cyclic adenosine 
monophosphate (AMP) by the stimulation of adenylyl cyclase. [13] If 
the ovum is fertilised, implantation takes place about 7 days later, and 
almost at once the developing trophoblast begins secreting human 
chorionic gonadotropin (hCG) into the maternal circulation, thereby 
sustaining the functional life of the corpus luteum. During the second 
or third month of pregnancy, the developing placenta begins to 
secrete oestrogen and progesterone in collaboration with fetal adrenal 
glands, and thereafter the corpus luteum is not essential to continued 
gestation. Oestrogen and progesterone continue to be secreted in 
large amounts by the placenta up to the time of delivery. The rate of 
progesterone increases from a few mg per day secreted during the 
follicular phase of the cycle, to 10 - 20 mg during the luteal phase and 
to several hundred mg during the latter part of pregnancy.[6,10-12] 
APD is a rare disorder characterised by cyclic eruption of varying 
morphology and distribution.[9,14-16] The eruption is induced by 
hypersensitivity to endogenous progesterone, and typically occurs 
during the luteal phase of the menstrual cycle as serum levels of 
this hormone increase. Partial to complete resolution occurs within 
days of menstruation, with recurrence during the next menstrual 
cycle. The eruption may be localised or generalised. Sensitisation 
with exogenous oestrogen in oral contraceptives may be an inciting 
factor in some cases.[8,9,17] Pregnancy may either worsen or improve 
the condition.[6,9] APD symptoms range from minor to severe skin 
presentations to severe systemic complications such as symptoms of 
asthma or anaphylaxis.[6,18-20] Dermatological manifestations of APD 
include: urticaria, angio-oedema, eczema, erythema multiforme, 
stomatitis, folliculitis, papulopustular/papulovesicular lesions, 
Stephens-Johnson syndrome, vesiculobullous reactions, dermatitis 
herpetiformis-like rash and mucosal lesions.
The pathogenesis of APD is unknown. It is believed both endo- and 
exogenous progesterones at some stage stimulate immunoglobulin E 
(IgE) synthesis. This mechanism has still not been clearly investigated, 
especially on endogenous progesterone.[21-24] Some authors have 
suggested that hydrocortisone or 17-α-hydroxyprogesterone have 
cross-sensitivity with progesterone and may cause initial sensitisation, 
but this has not been observed in all studies.[6,9] Some researchers have 
linked APD with specific antibodies, this having been established 
by using immunofluorescent techniques and basophil degranulation 
tests. Skin test results with progesterone have shown immediate 
reactions (within 30 minutes), delayed reactions (24 - 48 hours 
later) and reactions with both immediate and delayed features.[4,6,18,25] 
This presumably indicates both type I and type IV hypersensitivity 
reactions. Progesterone has also been reported to have a direct 
histamine-releasing effect on mast cells and in one study found an in 
vitro increase of an interferon-γ release assay, likely from TH1-type 
cytokines. Other researchers have correlated the presence of APD skin 
conditions with increased eosinophils levels.[4,6,18,25] 
In this case the first clinicians failed to link the appearance of 
current symptoms with APD. This is very common to many patients 
with APD.  The peculiarity of this case is on the timing, as the 
symptoms started immediately after the induction of medical abortion 
with mifepristone. Mifepristone (RU 486) is a derivative of the 
19-norprogestin norethindrone containing a dimethyl-aminophenyl 
substituent at the 11β-position.[13,26] It is a potent competitive antagonist 
of both progesterone and glucocorticoid, binding to their respective 
receptors. When administered in the early stages of pregnancy, 
Table 1. Treatment options used in APD
Treatment                                                            Advantage(s)
Pharmacological 
OCPs Usually tried as initial therapy
Antihistamines Fewer side-effects than most other 
therapies
Well tolerated, few side-effects
Conjugated oestrogens Avoids progesterone component of 
OCPs
Glucocorticoids Able to suppress multiple components 
of the immune system
Can be combined with other therapies
GnRH agonists Often used if OCPs and glucocorticoids 
are not effective
Alkylated steroids Can be combined with low-dose steroids
Tamoxifen Interferes with gonadal hormone 
receptors
Has been used successfully in patients 
unresponsive to conjugated oestrogen
Surgical 
Bilateral oophorectomy Definitive treatment, used if medical 
options unsuccessful
OCPs = oral contraceptives.
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mifepristone causes decidual breakdown by blocking the uterine 
progesterone receptors. This leads to the detachment of the blastocyst, 
which decreases HCG production. This in turn causes a decrease 
in progesterone secretion from the corpus luteum, which further 
accentuates decidual breakdown. Decreased endogenous progesterone 
coupled with the blockage of progesterone receptors in the uterus 
increases uterine prostaglandin levels and sensitises the myometrium 
to the contractile actions of prostaglandins.[26] Mifepristone also 
affects ovulation. If given accurately in the mid- to late-follicular 
phase, it delays follicle maturation and the LH surge, and ovulation 
occurs later than normal.[13,26] 
Blockage of progesterone receptors by the mifepristone triggers 
the decrease of progesterone levels in the body. One month after the 
abortion, the patient expected normal menstrual flow, but this did 
not happen. This might explain the further drop in oestrogen and 
progesterone levels or the decrease in sensitivity of the receptors 
after mifepristone blockage. This might have been taken as normal 
menstrual flow irregularity, but it explains the decrease from normal 
levels as a result of medical abortion. Most of the receptors in the 
body have a common characteristic of increasing or accelerating the 
action of the hormone or chemical immediately after the blockage 
or when the hormone levels increase above the normal level. [11,12] 
Increased receptor sensitivity after blockage is very common. 
Sensitivity increase from endogenous progesterone after mifepristone 
blockage can also be due to a negative feedback mechanism as 
a result of the production of progesterone. With the decrease in 
the level of progesterone immediately after medical abortion, the 
hormonal control mechanism of the progesterone might have shifted 
and caused an abrupt increase in the production of the hormone at 
the corpus luteum and adrenal cortex, causing APD. This can be 
explained by the increase of sensitivity to progesterone confirmed by 
the skin allergen test. As explained above, the pathogenesis of APD 
is not clearly known, but in this case the increase in progesterone 
levels 1 month after medical abortion might have stimulated the IgE 
synthesis, hence causing both type I and type IV hypersensitivity 
reactions. 
APD is usually resistant to conventional therapy such as anti-
histamines.[6] The use of systemic glucocorticoids, usually in high 
doses, has been reported to control the cutaneous lesions of APD in 
some cases.[4,6,18,25] This patient was also treated with topical steroids 
prior to our confirmed diagnosis. Several treatment modalities have 
been used in the treatment of APD. The most used are the ones that 
attempt to inhibit the secretion of endogenous progesterone by the 
suppression of ovulation.[2,6] Table 1 lists some of the pharmacological 
and surgical strategies used in APD management. OCPs are often 
tried as initial therapy, but have had limited success, possibly due to 
the fact that virtually all OCPs have a progesterone component.[6] In 
this case, OCPs worked very well and there was no need to change the 
regimen. Some clinicians also reported using conjugated oestrogens. 
However, due to the increased risk of endometrial carcinoma with 
unopposed conjugated oestrogens, this treatment is not commonly 
used.[2,6,27] 
GnRH agonists, such as buserelin and triptorelin, have been used to 
induce remission of symptoms by causing ovarian suppression.[6,28-30] 
However, side-effects include symptoms of oestrogen deficiency (hot 
flushes, vaginal dryness and decreased bone mineral density) and 
oestrogen supplementation may be needed.[6,25] Alkylated steroids 
such as stanozol have been used to successfully suppress ovulation, 
sometimes in combination with chronic low doses of corticosteroids. 
Side-effects of alkylated steroids include abnormal facial or body 
hair growth, hepatic dysfunction and mood disorders.[6] Thorough 
evaluations should be made if these are given to a patient. 
In many cases, anti-oestrogens have been used, most commonly 
tamoxifen, which can also suppress ovulation.[8,31] Though reported 
to be used by many clinicians, tamoxifen has shown to be associated 
with symptoms of oestrogen deficiency and increased risk of venous 
thrombosis and cataract formation. Extra monitoring is important 
if it is given to patients with high risk.[6,8,31] Surgery has been used in 
some severe cases of APD. This line of management is usually taken 
after medical options have failed. Bilateral oophorectomy is normally 
used to control severe forms of APD symptoms.[6,8,31]  
Conclusion
This was a case of APD which was triggered by increased sensitivity 
of endogenous progesterone caused by medical abortion. A positive 
intradermal test with progesterone confirmed the diagnosis, and the 
response to oral contraceptives was prompt and dramatic. This is 
one of the rare cases of APD that was induced immediately after a 
successful medical abortion.
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